Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2003-01-30
2008-12-30
O'Hara, Eileen B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S139100, C424S137100, C514S002600
Reexamination Certificate
active
07470428
ABSTRACT:
The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
REFERENCES:
patent: 6084083 (2000-07-01), Levinson
patent: 6562343 (2003-05-01), Levinson
patent: 6632608 (2003-10-01), Glimcher et al.
patent: 2005/0191721 (2005-09-01), Kuchroo et al.
patent: WO 03/002722 (2003-01-01), None
patent: WO 2005/033144 (2005-04-01), None
Beatty et al. J. Immunology, 2000, 165:5502-5508.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Bonnefoy, Cancer Vaccine, Expert Opin. Ther. Targets 2004, 8(6):521-525.
Nelson et al. Journal of Immunology, 2001, vol. 166: 5557-5566.
Genbank Accession No. AAL65156—T cell immunoglobulin mucin-3 [Mus musculus] Feb. 11, 2002.
Genbank Accession No. AAL65157—T cell immunoglobulin mucin-3 [Homo sapiens] Feb. 11, 2002.
Genbank Accession No. AAL65158—T cell immunoglobulin mucin-3 [Homo sapiens] Feb. 11, 2002.
Genbank Accession No. AF450241—Mus musculus T cell immunoglobulin mucin-3 mRNA, complete cds Feb. 11, 2002.
Genbank Accession No. AF450242—Homo sapiens clone 1 T cell immunoglobulin mucin-3 (TIM3) mRNA, complete cds Feb. 11, 2002.
Genbank Accession No. AF450243—Homo sapiens clone 2 T cell immunoglobulin mucin-3 (TIM3) mRNA, complete cds Feb. 11, 2002.
Gordon EJ et al. (1995) Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis.J Neuroimmunol62:153-60.
Huitinga I et al. (1990) Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages.J Exp Med172:1025-1033.
McIntire JJ et al. (2001) Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family.Nat Immunol2:1109-1116.
Monney L et al. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.Nature415:536-541.
Mosmann TR et al. (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.J Immunol136:2348-57.
Sallusto F et al. (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.J Exp Med187:875-83.
Syrbe U et al. (1999) Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression?Springer Semin Immunopathol21:263-85.
Tran EH et al. (1998) Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice.J Immunol161:3767-75.
Venkataraman C et al. (2000) Cutting edge: Chandra, a novel four-transmembrane domain protein differentially expressed in helper type 1 lymphocytes.J Immunol165:632-36.
Waldner H et al. (2000) Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor.Proc Natl Acad Sci USA97:3412-17.
Kuchroo VJ et al. The TIM gene family: emerging roles in immunity and disease.Nat Rev Immunol. Jun. 2003;3(6):454-62.
Beatty, et al., “IFN-γ Can Promote Tumor Evasion of the Immune System in Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen”, The Journal of Immunology, (2000, 165: pp. 5502-5508.
Monney, L., et al. “A Novel Cell Surface Protein, TIM-3, Expressed on TH1 Cells Promotes Macrophage Activation and Enhances Autoimmune Disease”, Faseb Journal, Bethesda, US, vol. 16, No. 5, p. A1062 (2002).
McIntire, J., et al. “Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene Family”, Nature Immunology, GB, vol. 2, No. 12, pp. 1109-1116 (2001).
Sabatos, C., et. “Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance”, Nature Immunology, GB, vol. 4, No. 11, pp. 1102-1110 (2003).
Myers, et al. “The TIM gene family regulates autoimmune an allergic disases”, Trends in Molecular Medicine, vol. 11, No. 8, pp. 362-269, (2005).
European Patent Office/EP Examination Report for Application No. 03723627.0-2402, Mailing Date: Jun. 16, 2006.
Freeman Gordon J.
Gaglia Jason L.
Greenfield Edward A.
Kuchroo Vijay
Monney Laurent
Dana-Farber Cancer Institute
Kim Yunsoo
Nixon & Peabody LLP
O'Hara Eileen B.
The Brigham and Women's Hospital, Inc.
LandOfFree
Compositions and methods related to TIM-3, a Th1-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods related to TIM-3, a Th1-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods related to TIM-3, a Th1-specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4038781